Pharmacological review demonstrates potent serum urate reduction with febuxostat in gout, highlighting its utility for severe disease and patients with renal or hepatic impairment.
Febuxostat is a novel, nonpurine, selective inhibitor of xanthine oxidase (NP-SIXO), recently approved in the European Union. Febuxostat shows high, long-term efficacy for the reduction of serum urate (SU) levels, showing linear pharmacokinetics at approved doses, and its pharmacokinetics are not clinically significantly influenced by the presence of mild-to-moderate renal or liver function impairment. The clinical applicability of febuxostat should have a significant impact in patients with the highest baseline SU levels, the most severe gout, previous adverse events with other urate-lowering drugs or no availability of alternative urate-lowering drugs after failure to properly control SU levels during urate-lowering therapy. Febuxostat may become an interesting choice in our use of xanthine oxidase inhibitors.
No takes yet. Share an insight, caveat, or question.
Pérez-Ruiz et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: